Misonix (MSON), SonoSpine Enter Exclusive Partnership
- Wall Street dips on Trump protectionism, Qualcomm drag
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- After-Hours Stock Movers 1/23: (REXX) (MRCY) (SYNC) Higher; (FSM) (OCUL) (CASC) Lower (more...)
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Misonix, Inc. (Nasdaq: MSON) announced a partnership with SonoSpine, LLC ("SonoSpine"), an international neurosurgical practice specializing in ultrasonic spine surgery (www.sonospinesurgery.com). Misonix's innovative ultrasonic devices paired with SonoSpine's revolutionary approach to spine surgery is expected to accelerate the development and application of next generation ultrasonic surgery.
"Innovation is the key driver in improving patient outcomes. We are proud to collaborate with Misonix as we continue to develop and implement ultrasonic surgical tools and techniques for the spine which dramatically improve patient outcomes," said Dr. Dilantha B. Ellegala, founder and surgeon-in-chief of SonoSpine. Misonix and SonoSpine share mutual corporate cultures which are committed to pioneering higher quality health care through technological innovation. This exclusive agreement will align these values to accelerate the development of such technologies. Moreover, our concentrated and unified efforts will promote broader and responsible adoption of these technological advances."
A joint clinical database will support Misonix's development of next generation devices while providing critical metrics for SonoSpine's continued success in improving patient care. Access to SonoSpine's clinical facilities allows new opportunities for Misonix to engineer from the surgeon's perspective within the operating suite. To widen the framework of ultrasonic therapies, plans include joint device development, clinical outcomes evaluation, and a shared ultrasonic training facility where key opinion leaders and researchers can meet to fully leverage SonoSpine's surgical approach and tap into Misonix's extensive research and product development capabilities.
"This strategic partnership that we've entered into with Dr. Ellegala, and his team at SonoSpine, is an important milestone for Misonix. Our engineers and marketing team, working in close concert with the SonoSpine surgeons, will not only create best-in-class innovative ultrasonic surgical instruments, but also collaborate on the development of entirely new surgical procedures and techniques that would otherwise not be possible," concluded Scott Ludecker, Senior Vice President of Global Sales and Marketing with Misonix.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stonemor Partners (STON) Announces Resignation of CFO Sean McGrath
- Theravance Biopharma (TBPH) Reports Interim Data from TOUR Study in Oral Presentation at SCCM
- Novelion Therapeutics (NVLN) Announces Acceptance of MAA for Metreleptin
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!